Galderma

Galderma is a Swiss skin-health company based in Zug that develops dermatology products across three areas: injectable aesthetics, dermatological skincare, and therapeutic dermatology. It is the parent company behind several brands familiar to consumers and clinicians, including Cetaphil, Differin, Restylane and Sculptra. The company was founded in 1981 as a joint venture between L'Oréal and Nestlé [7], and it describes itself as a company devoted solely to the skin.

The business is active and publicly traded. Following a 2024 listing on the SIX Swiss Exchange, Galderma operates in roughly 100 countries and reports more than 7,600 employees. The company positions itself as the only fully scaled, pure-play dermatology company and states an ambition to become "the undisputed dermatology powerhouse."

Although Galderma was created in 1981, its roots reach back two decades earlier. The company traces its lineage to Owen, a dermatology business founded in Dallas, Texas in 1961 [7]. In 1979, dermatologist Hans Schaefer established the International Center for Dermatological Research (CIRD) in Sophia Antipolis, France, with the support of L'Oréal's then chief executive François Dalle [7]. Two years later, L'Oréal and Nestlé formalised the partnership, combining cosmetic-science and nutrition expertise into a venture dedicated exclusively to dermatology. First commercial operations began in 1986.

Galderma's ownership has changed hands several times. From its founding it was a shared venture between L'Oréal and Nestlé. In 2014, Nestlé bought back L'Oréal's stake for €3.1 billion and folded the business into a new Nestlé Skin Health unit [7]. Five years later, in 2019, Nestlé sold Galderma for $10.2 billion to a consortium led by the investment firm EQT, alongside the Abu Dhabi Investment Authority and PSP Investments [7].

That private-equity ownership ended in March 2024, when Galderma went public on the SIX Swiss Exchange at CHF 53 per share [7]. The carve-out from Nestlé Skin Health made it, by Wikipedia's account, the largest independent global dermatology company [7].

The company has also grown through acquisition. It bought the Swedish medical-device maker Q-Med in 2010 [7], a deal that brought the Restylane filler line into the portfolio, and acquired the California-based professional-skincare company Alastin in 2021 [7].

Galderma's portfolio spans prescription medicines, professional aesthetic treatments and consumer skincare. Its consumer and over-the-counter skincare brands include Cetaphil, marketed for sensitive skin; Benzac, an acne range; and Differin, a topical retinoid based on the ingredient adapalene. Of these, Cetaphil is described by the company as a skincare brand recommended by dermatologists for more than 70 years [2].

In injectable aesthetics, the company markets the hyaluronic-acid fillers and Skinboosters sold under the Restylane name, the collagen-stimulating treatment Sculptra, and the botulinum toxin type A products Dysport and Azzalure. Its therapeutic dermatology range covers prescription treatments for conditions such as acne, rosacea and fungal nail infection, including Epiduo, Soolantra, Oracea and Loceryl. Across these brands the company works with active ingredients including adapalene, hyaluronic acid, botulinum toxin type A, benzoyl peroxide, brimonidine and ivermectin.

The company frames itself around science-based dermatology and reports a substantial clinical pipeline: by its own account it has conducted more than 170 clinical trials and received some 300 major regulatory approvals since 2020 [4]. Recent regulatory milestones include United States Food and Drug Administration approvals in 2024 for Nemluvio, a treatment for the skin condition prurigo nodularis, and for nemolizumab in atopic dermatitis. Among its proprietary developments, Galderma has introduced Relfydess, which it describes as the first ready-to-use liquid neuromodulator made with its PEARL technology.

Galderma's stated purpose is "advancing dermatology for every skin story," a line it uses as its primary tagline. The company says that "everyone's skin is unique" and that it aims to offer premium brands fitting individual needs across the full spectrum of dermatology. It cites a heritage of more than 40 years of science-based innovation [1] and frames its identity around being dedicated to a single organ, the skin.

Galderma is an active, publicly listed company (SIX: GALD) with global operations and four manufacturing sites, located in Alby-sur-Chéran, France; Baie d'Urfé near Montreal, Canada; Uppsala, Sweden; and Hortolândia in São Paulo state, Brazil. Reported figures vary by fiscal year and source: the company reports 2025 net sales of $5.207 billion and more than 7,600 employees [4], while Wikipedia records revenue of $4.41 billion and 6,500 employees for 2024 [7]. Its most recent reported activity includes the 2025 net-sales figure and continued product approvals through 2024 and 2025.